AB&B Bio-Tech CO., LTD. JS (AB&B Bio-Tech-B, 02627.HK) has entered into a strategic cooperation agreement with Walvax Hong Kong Limited, a wholly-owned subsidiary of Shenzhen-listed Walvax Biotechnology Co., Ltd. (300014.SZ). The agreement, signed on 13 March 2026, focuses on overseas registration, sales and commercialisation of AB&B Bio-Tech’s core product, the trivalent subunit influenza vaccine “Huierkangxin 3”.

Huierkangxin 3, approved for domestic marketing in January 2026, is currently the first and only trivalent subunit influenza vaccine in China indicated for individuals aged six months and above. Leveraging Walvax Hong Kong’s established international distribution channels, the partnership aims to fast-track market penetration across Southeast Asia, Latin America, the Middle East and other Southern Hemisphere regions.

The announcement emphasises that the cooperation framework does not constitute a notifiable or connected transaction under Chapters 14 and 14A of the Hong Kong Listing Rules. A definitive business agreement is still pending; further disclosures will be made in accordance with regulatory requirements. Shareholders and potential investors are advised to exercise caution when trading the company’s securities.